Floatz logo

ER-176

FTD

Mayo ClinicSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

24 Active assets in the FTD cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Mayo Clinic
Phase 4BBB
FLUDEOXYGLUCOSE
University of Michigan
Phase 4BB
CITALOPRAM
Sunnybrook Health Sciences Centre
Phase 4BB
LEMBOREXANT
Nova Scotia Health Authority
Phase 4BB
PITTSBURGH COMPOUND B UNLABELLED
Mayo Clinic
Phase 4BB

View all 41 →

Same molecule, other indications

ER-176 is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
55 / 100
View asset →
Alzheimer diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
demyelinating diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →